BridgeMD
Compares treatment options for Intracranial Atherosclerosis
Official title Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD
ClinicalTrials.gov ID: NCT06714526
What this study is testing
What is Point-of-Care CYP2C19 Testing?
Point-of-Care CYP2C19 Testing is an investigational medicine, being studied as a potential treatment for intracranial atherosclerosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Stroke is an important cause of death, disability, and memory problems in adults. The build-up of plaque in arteries inside the brain is known as "intracranial atherosclerotic disease" or "ICAD" for short, and can reduce blood flow in the brain.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Age ≥ 40 years old, male and female.
- TIA or ischemic stroke secondary to symptomatic atherosclerotic stenosis of 30- 99% involving the intracranial ICA or MCA or posterior circulation...
- Index TIA or ischemic stroke event occurred within past 30 days.
- Clinical indication for DAPT for at least 3 months.
You likely can't join if
- Any contraindication to DAPT.
- Any contraindication to use of clopidogrel (Plavix) or ticagrelor (Brilinta), such as pregnancy. A pregnancy test will be performed on all women of...
- Indication for chronic anticoagulation based on guideline recommendations or investigator's judgment (e.g., atrial fibrillation, mechanical heart...
- Intracranial arterial occlusion (i.e. 100% stenosis) responsible for the acute brain ischemia.
- Intracranial arterial stenosis secondary to causes other than atherosclerosis.
- Extracranial carotid disease with a plan for carotid revascularization.
See the full eligibility criteria
- Age ≥ 40 years old, male and female.
- TIA or ischemic stroke secondary to symptomatic atherosclerotic stenosis of 30- 99% involving the intracranial ICA or MCA or posterior circulation arteries as evidenced by CT or MR angiography.
- Index TIA or ischemic stroke event occurred within past 30 days.
- Clinical indication for DAPT for at least 3 months.
- Any contraindication to DAPT.
- Any contraindication to use of clopidogrel (Plavix) or ticagrelor (Brilinta), such as pregnancy. A pregnancy test will be performed on all women of child-bearing age prior to enrollment in the study.
- Indication for chronic anticoagulation based on guideline recommendations or investigator's judgment (e.g., atrial fibrillation, mechanical heart valve, intracardiac clot, dilated cardiomyopathy, ejection fraction...
- Intracranial arterial occlusion (i.e. 100% stenosis) responsible for the acute brain ischemia.
- Intracranial arterial stenosis secondary to causes other than atherosclerosis.
- Extracranial carotid disease with a plan for carotid revascularization.
- Intraluminal thrombus.
- Unstable subdural hematoma within 12 months of randomization not amenable to embolization.
- Previous spontaneous hemorrhagic stroke.
- Traumatic brain hemorrhage within 1 month of randomization.
- Living in a nursing home or requiring daily nursing care or assistance with activities of daily living.
- Intracranial tumor (except meningioma) or any intracranial vascular malformation.
- Life expectancy less than 6 months.
- Enrolment in another study that would conflict with the current study.
The study team makes the final eligibility decision.
Where it's taking place
- Calgary, Alberta, Canada
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Calgary, Alberta, Canada; Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.